Login / Signup

Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.

Paul BilloirVirginie BarbayLuc Marie JolyMarielle FreselMarie Hélène ChrétienVéronique Le Cam Duchez
Published in: The Annals of pharmacotherapy (2018)
We demonstrated a significant correlation between LMWH anti-Xa activity and rivaroxaban ( R2 = 0.947) or apixaban ( R2 = 0.959) concentration and a significant correlation between rivaroxaban and apixaban plasma concentration ( R2 = 0.972). A LMWH anti-Xa activity <0.50 IU/mL could exclude a plasma concentration of rivaroxaban and apixaban >30 ng/mL and indicate the feasibility of invasive procedure. Conclusion and Relevance: In the absence of a specific test, LMWH-calibrated anti-Xa assay could be used to determine the presence and evaluate the plasma concentration of oral anti-Xa inhibitors. However, these initial findings require confirmation using other chromogenic calibrated oral anti-Xa assays.
Keyphrases
  • venous thromboembolism
  • atrial fibrillation
  • pulmonary embolism
  • high throughput
  • public health
  • healthcare
  • emergency department